Join to view full profile
333 Cedar StreetP.O. Box 208042New Haven, CT 06520
Phone+1 203-200-5180
Fax+1 203-200-5170
Dr. Saperstein is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Nuclear Radiology, 2000 - 2001- New York Presbyterian Hospital (Columbia Campus)Residency, Radiology-Diagnostic, 1996 - 2000
Stanford Health Care-Sponsored Stanford UniversityResidency, Surgery, 1993 - 1995
Duke University School of MedicineClass of 1993
Certifications & Licensure
CA State Medical License 1994 - Present
NY State Medical License 1999 - 2028
CT State Medical License 2007 - 2027
FL State Medical License 2006 - 2017
NJ State Medical License 2001 - 2009
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Publications & Presentations
PubMed
- 1 citationsAdoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.Michael S Leapman, Jessica B Long, Sarah Westvold, Maximilian Rabil, Preston C Sprenkle
JCO Oncology Practice. 2026-02-03 - 3 citationsCost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation.Natalia Kunst, Jessica B Long, Preston C Sprenkle, Isaac Y Kim, Lawrence Saperstein
JAMA Network Open. 2025-10-01 - Impact of Concomitant Hormone Therapy on the Diagnostic Performance ofF-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B.Lawrence Saperstein, Steven P Rowe, Michael A Gorin, Kenneth J Pienta, Barry A Siegel
The Prostate. 2025-08-01
Press Mentions
Hormone Therapy Doesn’t Affect Prostate Cancer PET/CT ScansMay 7th, 2025
Radiologists Bring New Molecular Imaging Technology to YaleJanuary 19th, 2021
Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First PatientDecember 12th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: